CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) demonstrated for the first time that inhibiting the interleukin (IL)-1b pathway can lower the risk of cardiovascular events in patients with coronary artery disease (CAD) by about 17% (27). This evidence concerns the gene IL1B and coronary artery disorder.